Results 41 to 50 of about 168,585 (146)

Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) offer more efficient paclitaxel delivery into tumor cells with fewer side effects than conventional chemotherapies.
Hong Tan, Jing Hu, Shan Liu
doaj   +1 more source

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

PLoS ONE, 2021
Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory ...
J. Robert McCorkle, Justin W. Gorski, Jinpeng Liu, McKayla B. Riggs, Anthony B. McDowell, Nan Lin, Chi Wang, Frederick R. Ueland, Jill M. Kolesar   +8 more
doaj  

Paclitaxel Maculopathy [PDF]

Archives of Ophthalmology, 2007
Mandar M, Joshi, Bruce R, Garretson
openaire   +2 more sources

pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy

International Journal of Nanomedicine, 2012
Jae-Yoon Shin,1,* Yoosoo Yang,1,* Paul Heo,1 Ji-Chun Lee,1 ByoungJae Kong,1 Jae Youl Cho,1 Keejung Yoon,1 Cheol-Su Shin,2 Jin-Ho Seo,3 Sung-Gun Kim,4 Dae-Hyuk Kweon11Department of Genetic Engineering, College of Biotechnology and Bioengineering, and ...
Shin JY, Yang Y, Heo P, Lee JC, Kong BJ, Cho JY, Yoon K, Shin CS, Seo JH, Kim SG, Kweon DH   +10 more
doaj  

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients

Bangladesh Journal of Pharmacology, 2015
We investigated dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment on stage II-IV ovarian cancer patients.
Zhenhua Du, Xiaolin Ma
doaj  

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks

Scientific Reports
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences.
Nan Qin, Zhongliu Bian, Jingtao Chen
doaj   +1 more source

Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity

Journal of Pharmacological Sciences, 2016
Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats.
Kuniaki Tsutsumi, Takanori Kaname, Haruka Shiraishi, Takehiro Kawashiri, Nobuaki Egashira   +4 more
doaj   +1 more source

Cyclosporine A Decreased Paclitaxel Resistance in Prostate Cancer Cells by Inhibiting MTDH Expression

American Journal of Men's Health
This study aims to investigate the effect and mechanism of cyclosporine A (CsA) on paclitaxel-resistant prostate cancer cells. Paclitaxel-resistant prostate cancer cell lines were established by gradual increment method.
Jiangtao Li, Yuzhi Li, Xiaohong Zhang, Kun Liu, Shiping Yang, Zhang Liu, Sheng Cao, Dongfei Ren, Menghui Cui, Jia Su, Zewang Zhen, Donghong Zhang   +11 more
doaj   +1 more source

RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer

Clinical and Translational Medicine
Background Resistance to paclitaxel‐based chemotherapy is the major obstacle in triple‐negative breast cancer (TNBC) treatment. However, overcoming paclitaxel resistance remains an unsolved problem. The present study aimed to determine whether paclitaxel
Shumei Huang, Dongni Shi, Shuqin Dai, Xingyu Jiang, Rui Wang, Muwen Yang, Boyu Chen, Xuwei Chen, Lingzhi Kong, Lixin He, Pinwei Deng, Xiangfu Chen, Chuyong Lin, Yue Li, Jun Li, Libing Song, Yawei Shi, Weidong Wei   +17 more
doaj   +1 more source

Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells

BMC Cancer
Background Paclitaxel, a tubulin-binding agent, is a Food and Drug Administration-approved first-line drug for the treatment of non-small cell lung cancer (NSCLC), for both squamous and non-squamous cell lung carcinoma, with paclitaxel/carboplatin ...
Yanyan Lu, Wubin He, Xiaoxu Huang, Xuyang Xiao   +3 more
doaj   +1 more source